
Commercialization
Latest News

Latest Videos
Podcasts
More News

Pharma must align data, personalization, and cross-functional orchestration to deliver human-centered experiences that connect with patients, HCPs, and caregivers alike.

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a new rare disease treatment from Sanofi one month prior.

Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, stakeholder engagement, and innovative access strategies are key to long-term CGT success.

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and potentially, other IL-36–driven conditions.

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, being regulatorily compliant, and the rapid advancements in artificial intelligence.

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Brett Casper explores the marketplace complexities that manufacturers face regularly.

The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

A look at the actionable steps needed to elicit change.

Known as AVT05, the Alvotech medication is a proposed biosimilar to Simponi, prescribed to treat various inflammatory conditions.

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.